CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 61,300 shares, a decline of 6.6% from the December 15th total of 65,600 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average trading volume of 59,400 shares, the short-interest ratio is currently 1.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a report on Thursday, November 14th.

CalciMedica Stock Down 2.5 %

Shares of NASDAQ CALC traded down $0.08 during trading hours on Friday, reaching $3.09. 21,907 shares of the stock traded hands, compared to its average volume of 25,828. The company has a market capitalization of $41.65 million, a P/E ratio of -2.86 and a beta of 1.22. The company’s 50-day simple moving average is $3.13 and its two-hundred day simple moving average is $3.86. CalciMedica has a 52-week low of $2.05 and a 52-week high of $8.38.

Insider Activity at CalciMedica

In other CalciMedica news, major shareholder Sanderling Venture Partners Vi acquired 86,867 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average price of $3.75 per share, with a total value of $325,751.25. Following the completion of the acquisition, the insider now owns 814,300 shares of the company’s stock, valued at $3,053,625. This trade represents a 11.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO A. Rachel Leheny acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $3.75 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the chief executive officer now owns 130,926 shares of the company’s stock, valued at $490,972.50. The trade was a 18.03 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 252,744 shares of company stock valued at $942,510. Corporate insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CALC. PVG Asset Management Corp bought a new position in shares of CalciMedica during the 3rd quarter valued at $67,000. Atria Investments Inc grew its stake in shares of CalciMedica by 136.5% during the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock valued at $117,000 after buying an additional 15,296 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after buying an additional 22,525 shares during the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.